Digital versus digitised: common misconceptions about eConsent

Supported by:

20 July 2022

Shares

10

About this webinar

With today’s world centred around digital interaction, it may surprise you that a recent Medable poll found the informed consent process remains rooted in paper.

However, this reliance comes at a cost. Low enrolment, poor patient retention and issues around site compliance lead to audits, inspection findings and trial delays.

With Nature stating that almost 60 percent of clinical professionals expect eConsent adoption to continue post-COVID-19, it is clear the benefits behind digital consent have garnered trust.

So, why does adoption continue to increase, albeit slowly?

In this on-demand webinar attendees will learn about the common misconceptions surrounding eConsent, as well as the benefits they can realise through a digitally-enabled approach.

Specifically, you’ll learn:

• The myths that continue to persist around eConsent
• The difference between eConsent and eSignature
• How to improve comprehension with patient-centric consent
• How to use a digital consent management system to improve trial compliance, quality and oversight

Our speakers

Andrew Mackinnon, Vice President & General Manager, Medable

As General Manager for eConsent, Andrew oversees the development of the eConsent product, as well as the implementation of eConsent in Medable studies, ensuring that Medable’s clients can run high quality, effective and efficient decentralised clinical trials. Andrew has 20 years of experience in managing clinical trials at large pharma, biotech and CRO companies, most recently as a Senior Director in one of Covance’s therapeutic area delivery groups and as Head of Business Performance. From his involvement in one of the earliest deployments of decentralised methodologies, he has been passionate about the benefits that this approach can bring in reducing the burden of clinical research on both sites and patients – and looks to leverage his broad operational expertise to improve how this approach is utilised.

Alex Burrington, Clinical Technology Innovations Principal, Vertex

Alex Burrington is Clinical Technology Innovations Principal at Vertex Pharmaceuticals. He leads innovative strategies and efforts for feasibility, recruitment and enrolment, while also focusing on site outreach. Alex also supports patient advocacy and partnerships with patient organisations to support study execution.